Clinical Trial Info

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Authored by


An interventional Phase 3 study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately. This trial will evaulate the administration on 1797 particpants all 65 years of age or older.


Pfizer announced on September 29, 2021 top-line results of this study.  

“We are encouraged by these results showing that these two vaccines can be administered at the same time without affecting the immune protection provided by either vaccine or changing the safety profile,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “This study adds to the body of evidence further supporting that pneumococcal conjugate vaccines may be coadministered with influenza vaccines, this time studied with the adjuvanted influenza vaccine. We are committed to vaccine development to help address needs across many respiratory diseases.”